Page last updated: 2024-12-05

mescaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Mescaline is a psychedelic drug that is found in the peyote cactus. It is a phenethylamine alkaloid with a chemical structure similar to that of dopamine, norepinephrine, and serotonin. Mescaline produces a wide range of effects, including visual hallucinations, changes in perception, and altered states of consciousness. It is thought to exert its effects by acting as an agonist at serotonin receptors in the brain. Mescaline has a long history of use in indigenous cultures of the Americas for religious and spiritual purposes. It has also been used in psychotherapy and for recreational purposes. Mescaline is a Schedule I controlled substance in the United States, meaning it is illegal to possess, manufacture, or distribute. Research on mescaline is ongoing, with a focus on understanding its effects on the brain and its potential therapeutic applications.'

Mescaline: Hallucinogenic alkaloid isolated from the flowering heads (peyote) of Lophophora (formerly Anhalonium) williamsii, a Mexican cactus used in Indian religious rites and as an experimental psychotomimetic. Among its cellular effects are agonist actions at some types of serotonin receptors. It has no accepted therapeutic uses although it is legal for religious use by members of the Native American Church. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mescaline : A phenethylamine alkaloid that is phenethylamine substituted at positions 3, 4 and 5 by methoxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Lophophoragenus[no description available]CactaceaeThe cactus plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. Cacti are succulent perennial plants well adapted to dry regions.[MeSH]

Cross-References

ID SourceID
PubMed CID4076
CHEMBL ID26687
CHEBI ID28346
SCHEMBL ID34190
MeSH IDM0013457

Synonyms (72)

Synonym
benzeneethanamine, 3,4,5-trimethoxy-
phenethylamine, 3,4,5-trimethoxy-
tmpea
nsc-30419
mescalin
benzeneethanamine,4,5-trimethoxy-
nsc30419
wln: z2r co1 do1 eo1
ethane,4,5-trimethoxyphenyl)-
mezcaline
3,5-trimethoxyphenethylamine
3,5-trimethoxyphenylethylamine
mezcalin
mescline
mezcline
DIVK1C_000984
KBIO1_000984
brn 1374088
dea no. 7381
nsc 30419
einecs 200-190-7
mescalin [german]
OPREA1_166025
IDI1_000984
3,4,5-trimethoxyphenylethylamine
3,4,5-trimethoxy-b-phenethylamine
benzeneethanamine, 3,4,5-trimethoxy- (9ci)
phenethylamine, 3,4,5-trimethoxy- (8ci)
ethane, 1-amino-2-(3,4,5-trimethoxyphenyl)-
3,4,5-trimethoxybenzeneethanamine
2-(3,4,5-trimethoxyphenyl)ethylamine
3,4,5-trimethoxyphenethylamine
C06546
mescaline
54-04-6
NINDS_000984
1-amino-2-(3,4,5-trimethoxyphenyl)ethane
2-(3,4,5-trimethoxyphenyl)ethanamine
CHEBI:28346 ,
meskalin
mezcalina
mescalina
CHEMBL26687 ,
AKOS000277426
bdbm50059891
NCGC00247674-01
2-(3,4,5-trimethoxyphenyl)-ethyl-amine
constituent of peyote cacti
hsdb 7503
rho99102vc ,
unii-rho99102vc
2-(3,4,5-trimethoxy-phenyl)-ethylamine
mescaline [mi]
mescaline [hsdb]
m (psychedelic)
mescaline [mart.]
mescaline [who-dd]
SCHEMBL34190
(3,4,5-trimethoxy)-benzylmethylamine
3,4,5-trimethoxy-phenethylamine
3,4,5-trimethoxyphenethyl-amine
2-(3,4,5-trimethoxyphenyl)ethanamine #
DTXSID80202303 ,
J-505719
Q193140
SB37575
dtxcid40124794
ethane, 1-amino-2-(3,4,5-trimethoxyphenyl)-(chemid)
3,4,5-trimethyoxybenzeneethanamine
mescaline (mart.)
3,4,5-trimethoxyphenylethylamine(chemid)
dea no. 7381(chemid)

Research Excerpts

Overview

Mescaline is a naturally occurring alkaloid found in cacti, mainly in the peyote cactus (Lophophora williamsii) and in the Echinopsis genus. Its main hallucinogenic effects are mediated via its 5HT2A receptor agonist action. Mescaline was historically used ceremonially by Indigenous and Latin American populations.

ExcerptReferenceRelevance
"Mescaline is a naturally occurring alkaloid found in cacti, mainly in the peyote cactus (Lophophora williamsii) and in the cacti of the Echinopsis genus."( Mescaline: The forgotten psychedelic.
Campbell, I; Dyck, JRB; Narine, KAD; Nutt, DJ; Vamvakopoulou, IA, 2023
)
3.07
"Mescaline is a serotonin 5HT2A/2C receptor agonist, with its main hallucinogenic effects being mediated via its 5HT2A receptor agonist action. "( Mescaline: The forgotten psychedelic.
Campbell, I; Dyck, JRB; Narine, KAD; Nutt, DJ; Vamvakopoulou, IA, 2023
)
3.8
"Mescaline is a naturally occurring psychoactive phenethylamine found in several cacti and historically used ceremonially by Indigenous and Latin American populations. "( The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.
Davis, AK; Davis, D; Dolan, SB; Haas, TF; Lancelotta, R; Ramaekers, JG; Timmermann, C; Uthaug, MV, 2022
)
2.49
"Mescaline is a nonselective, seretonin receptor agonist."( Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.
Kovacic, P; Somanathan, R,
)
1.14
"Mescaline is a nonselective serotonin receptor agonist. "( Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose.
Balíková, M; Bubeníková-Valesová, V; Horácek, J; Pálenícek, T, 2008
)
3.23

Effects

Mescaline has a documented use dating back 5700 years. Mescaline increased spontaneous motility and decreased cholinesterase activity.

ExcerptReferenceRelevance
"Mescaline has a documented use dating back 5700 years."( Development and clinical application of an LC-MS-MS method for mescaline in urine.
Beck, O; Björnstad, K; Helander, A, 2008
)
1.31
"Mescaline has a documented use dating back 5700 years."( Development and clinical application of an LC-MS-MS method for mescaline in urine.
Beck, O; Björnstad, K; Helander, A, 2008
)
1.31
"The mescaline has shown to be active both on behaviour (increasing the spontaneous motility) and on biochemistry (decreasing the total cholinesterase activity)."( [Effect of mescaline on cerebral cholinesterases and on exploratory behavior in rats].
Carbonatto, P; Torre, E; Torre, M, 1979
)
1.13

Actions

ExcerptReferenceRelevance
"Mescaline caused an increase in food consumption."( Mescaline action on "memory decay" and "problem solving" behavior in the rat.
Baroli, A; Cassone, MC; Molinengo, L; Orsetti, M, 1986
)
2.44

Treatment

Mescaline treatment of brain-cortex slices removed a portion of the endogenous spermidine from ribosomes. Mescaline, with pCPA pretreatment, may be associated with long-term behavioral effects. All rats treated with this combination were later found to be poor avoiders.

ExcerptReferenceRelevance
"Mescaline-treated rats (50 or 250 mg) rarely struck each other, but engaged in nearly lethal biting."( Severe aggression in rats induced by mescaline but not other hallucinogens.
Elliott, ML; Gorelick, DA; Sbordone, RJ; Wingard, JA, 1979
)
1.25
"Mescaline, with pCPA pretreatment, may be associated with long-term behavioral effects; all rats treated with this combination were later found to be poor avoiders, unable to achieve a stable baseline of good avoidance."( Parachlorophenylalanine potentiates facilitatory effects of mescaline on shuttlebox escape/avoidance in rats.
Gillin, JC; Stoff, DM; Wyatt, RJ, 1976
)
1.22
"2. Mescaline treatment of brain-cortex slices removed a portion of the endogenous spermidine from ribosomes and this removal was significantly prevented when spermidine was present during mescaline treatment."( Mescaline-induced changes of brain-cortex ribosomes. Role of sperimidine in counteracting the destabilizing effect of mescaline of brain-cortex ribosomes.
Antopol, W; Datta, RK; Ghosh, JJ, 1971
)
2.21

Toxicity

ExcerptReferenceRelevance
" Psychedelics are generally considered to be physiologically safe with low toxicity and low addictive potential."( Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół, A, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic behaviour conformed to the two-compartment open model."( Pharmacokinetic parameters of mescaline in rabbits.
Heyndrickx, A; Van Peteghem, C; Van Zele, W,
)
0.42
"Mescaline pharmacokinetic and pharmacodynamic aspects were searched in books and in PubMed (U."( Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.
da Silva, DD; Dinis-Oliveira, RJ; Pereira, CL, 2019
)
2.2
" Its pharmacodynamic mechanisms of action are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors, and therefore clinical effects are similar to those elicited by other psychoactive substances, such as lysergic acid diethylamide (LSD) and psilocybin, which include euphoria, hallucinations, depersonalization and psychoses."( Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.
da Silva, DD; Dinis-Oliveira, RJ; Pereira, CL, 2019
)
0.76

Dosage Studied

ExcerptRelevanceReference
"A dosage regimen of lysergic acid diethylamide (LSD) that reliably produces behavioral tolerance in rats was evaluated for effects on neurotransmitter receptor binding in rat brain using a variety of radioligands selective for amine receptor subtypes."( Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Buckholtz, NS; Freedman, DX; Potter, WZ; Zhou, DF, 1990
)
0.28
" The dose-response curves for the phenethylamine hallucinogens were shifted significantly to the right and to a greater degree than were those for the indolealkylamine hallucinogens."( The 5HT2 antagonist pirenperone reverses disruption of FR-40 by hallucinogenic drugs.
Mokler, DJ; Rech, RH; Stoudt, KW, 1985
)
0.27
" The results show that at equivalent dosage schedules with repeated high dosages, Go-10213 is devoid of adverse central and peripheral neural effects in monkeys; cats and dogs, whereas unequivocal evidence of metronidazole neurotoxicity was obtained in all the three species."( Pharmacological profile of 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go-10213), a new antiprotozoal agent, in comparison with metronidazole.
Acharya, TK; David, J; Grewal, RS; Kaul, CL; Nargunde, HS; Ringe, SY; Wagle, GP, 1985
)
0.27
" Dose-response and time-response curves were obtained."( Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
Appel, JB; Koerner, J, 1982
)
0.26
" Furthermore, combinations of the hallucinogens interact with potentiation to cause FR-40 pausing, whereas a variety of non-hallucinogenic psychoactive drugs failed to shift the dose-response patterns of pausing for DOM or LSD."( Neurotransmitter basis of the behavioral effects of hallucinogens.
Commissaris, RL; Rech, RH, 1982
)
0.26
" Inefficient demethylation is in keeping with the various drug properties, such as requirement for high dosage and slow acting."( Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.
Kovacic, P; Somanathan, R,
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
hallucinogenDrugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
phenethylamine alkaloid
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.38000.00020.667710.0000AID267699
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki3.78670.00010.601710.0000AID267698; AID385347; AID5501
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.55100.00000.385510.0000AID5177
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.30280.00010.954910.0000AID5857
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.79510.00030.769310.0000AID5386
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)EC50 (µMol)24.00000.00180.05350.1780AID5702
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd2.23870.00042.58328.5114AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)EC50 (µMol)5.96670.00010.49294.0000AID267700; AID5460; AID5467
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd2.23870.00012.62198.5114AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd2.23870.00012.29338.5114AID6406
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd2.23870.00042.47358.5114AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd2.23870.00012.70068.5114AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd2.23870.00082.62148.5114AID6406
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd2.23870.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd2.23870.00082.62148.5114AID6406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID5389Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID178955Effective dose showing 50% Drug Discrimination in LSD trained rats (number of animals tested = 8-12)1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID1134692Hyperthermic activity in New Zealand rabbit assessed as mean maximum rise in rectal temperature at 0.25 to 21.2 umol/kg administered in marginal ear vein as solution of amine hydrochloride in nonpyrogenic saline relative to l-(2,5-dimethoxy-4-methylphenyl1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Monomethylthio analogues of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane.
AID5467Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID5386Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID385350Agonist activity at Sprague-Dawley rat 5HT2A receptor by drug discrimination assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID1149528Agonist activity at serotonin receptor in sheep umbilical artery assessed increase of mescaline-induced contraction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogues.
AID267699Displacement of [125I]DOI from rat 5HT2C receptor2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID178403Effective dose in rats trained on 1 mg/kg DOM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID125221In vitro bovine plasma monoamine oxidase deamination without semicarbazide1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline.
AID185557Maximum 5-HT stimulation was determined in cloned rats2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID5702Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID385349Lipophilicity of compound by immobilized artificial membrane column containing phosphatidylcholine head groups HPLC2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID267700Activity at rat 5HT2A receptor assessed as 5-HT-stimulated IP3 accumulation2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID5460Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID5861Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID197121Ability to inhibit accumulation [3H]DA in rat whole brain synaptosomes1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID4206Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID1146450Competitive antagonist activity at 5-HT serotonin receptor in Sprague-Dawley rat stomach fundus model assessed as inhibition of 5-HT-induced contractile response1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID5182Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID125220In vitro bovine plasma monoamine oxidase deamination with semicarbazide1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline.
AID5857Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID5177Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID385347Displacement of [3H]ketanserin from 5HT2A receptor in Sprague-Dawley rat brain by liquid scintillation spectroscopy2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
AID5501Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID197120Ability to inhibit accumulation [3H]5-HT in rat whole brain synaptosomes1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID19263Log value of hallucinogenic activity was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID89086Compound was tested for the psychotropic effect in human (activity is expressed in mescaline unit)1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline.
AID267701Hallucinogenic activity in rat2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID88883Hallucinogenic activity i.e; ratio of effective dose of mescaline to the effective dose in human1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID19470Partition coefficient (logP)1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
AID11495301-Octanol-water partition coefficient, log P of the compound at pH 81977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogues.
AID90252Psychotomimetic potency of compound relative to that of mescaline(Human potency of mescaline = 1 MU)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Sulfur analogues of psychotomimetic agents. 3. Ethyl homologues of mescaline and their monothio analogues.
AID267698Displacement of [125I]DOI from rat 5HT2A receptor2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (991)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990868 (87.59)18.7374
1990's37 (3.73)18.2507
2000's32 (3.23)29.6817
2010's28 (2.83)24.3611
2020's26 (2.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (1.30%)5.53%
Reviews80 (7.43%)6.00%
Case Studies23 (2.14%)4.05%
Observational0 (0.00%)0.25%
Other960 (89.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparing Efficacy and Safety of Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis: A Prospective, Multicenter,Real-world Study [NCT05933213]Phase 4205 participants (Anticipated)Interventional2023-07-06Not yet recruiting
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness [NCT04849013]Phase 116 participants (Actual)Interventional2021-08-11Completed
Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects [NCT04227756]Phase 130 participants (Anticipated)Interventional2020-05-19Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]